Home Sleep Testing in Neuromuscular Disease Patients (HSTNMD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Lay Summary Patients with severe neuromuscular develop hypoventilation, which leads to elevated carbon dioxide levels. Measuring only oxygen saturation levels with pulse oximetry may be inadequate. End tidal carbon dioxide levels or arterial blood gases should be measured periodically, depending on the clinical condition of the patient. A thorough review of systems will help define any problems. Patients who are hypoventilating often have elevated carbon dioxide levels at night and complain of a morning headache, restlessness or nightmares, and poor quality sleep. This may cause daytime sleepiness. Insufficient respiration with hypoxia may occur later, especially if the lung is damaged by chronic aspiration.
We propose to evaluate the use of the Nonin LifeSense monitor in home evaluation of respiration, oxygen level, heart rate, and carbon dioxide level and to develop interpretation of the results that will lead to appropriate interventions for apnea, and insufficient respiration.
Relevance to MDA Fewer than one per cent of the Muscular Dystrophy Association have pulmonologists as co-directors.Late referral of progressive restrictive lung disease leads to invasive support of respiratory failure. Early initiation of non invasive ventilation techniques requires patience on the part of the caregiver and exploration of mask interfaces and ventilation techniques. In addition, the development of new therapies, currently manifested through enhanced diagnostic accuracy, will require new signal for initiation and in the assessment of success or failure.
Aims Aim 1. To assess the utility of a small portable device (LifeSense Monitor Nonin Medical Inc. Plymouth Minnesota) with extended recording capabilty to provide accurate diagnosis of hypoventilation.
Aim 2. To provide an easily interpretable report defining sleep hypoxemia, hypercapnea, and apnea.
Aim 3. To promote early evaluation and treatment of the respiratory problems in centers that do not have pumonologists as these are essential to prognosis, whether of survival or of quality of life, in neuromuscular diseases.
| Condition | Intervention |
|---|---|
|
Neuromuscular Disease |
Other: Evaluation for Nocturnal non invasive ventilation |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Home Sleep Testing in Neuromuscular Disease Patients |
- 1. End tidal CO2 catheter is tolerated for six hours or more [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- 1. Interpretable data are captured for oximetry, heart rate, and end-tidal CO2 [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- 2. An interpretive report is generated that will guide the non-pulmonary physician in potential interventions [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- 2. Patients and parents are able to apply the monitors at home and a six hour data set is collected [ Time Frame: 3 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 15 |
| Study Start Date: | July 2008 |
| Estimated Study Completion Date: | July 2012 |
| Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1SevereRLD,NMD
Patients with FEV1<40%
|
Other: Evaluation for Nocturnal non invasive ventilation
Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
|
|
2VerySevereRLD,NMD
FEV1<30%
|
Other: Evaluation for Nocturnal non invasive ventilation
Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
|
|
3NINV
FEV1<25%,on non invasive ventilation
|
Other: Evaluation for Nocturnal non invasive ventilation
Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
|
|
ModerateRLD,NMD
Patients with FEV1 40-50% of predicted
|
Other: Evaluation for Nocturnal non invasive ventilation
Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
|
Eligibility| Ages Eligible for Study: | 8 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population Description Patients from the Neuromuscular Disease Clinic at Ventura County Medical Center
Non-Probability Sample: invitation to volunteer
Neuromuscular Disease
Inclusion Criteria:
- Clinical diagnosis of neuromuscular disease
- Must have home caregivers
Exclusion Criteria:
- No home caregiver
Contacts and Locations| United States, California | |
| Pediatric Diagnostic Center | |
| Ventura, California, United States, 93003 | |
| Principal Investigator: | Chris Landon, MD | Landon Pediatric Foundation |
More Information
Additional Information:
Publications:
| Responsible Party: | Chris Landon MD |
| ClinicalTrials.gov Identifier: | NCT00695591 History of Changes |
| Other Study ID Numbers: | LS01 |
| Study First Received: | June 3, 2008 |
| Last Updated: | June 21, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Landon Pediatric Foundation:
|
Home sleep testing neuromuscular disease Neuromuscular disease patients with FEV1<50% of predicted |
Additional relevant MeSH terms:
|
Neuromuscular Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013